News | December 22, 2023
JB Pharma buys opthalmology brands from Novartis for Rs 964 Cr
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Development services for gene and cell therapies is planned to begin first in 2025
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Subscribe To Our Newsletter & Stay Updated
